MoneyWorks4Me

Sanjivani Paranteral - Quaterly Results

13 May 2024 Evaluate
The turnover for the March 2024 quarter moved up 58.38% to Rs. 128.64 millions as compared to Rs. 81.22 millions during the year-ago period.Good  Net Profit growth of 26.31% reported above the corresponding previous quarter figure of Rs. 9.96 millions to Rs. 12.58 millioins.Operating profit for the quarter ended March 2024 rose to 22.11 millions as compared to 13.85 millions of corresponding quarter ended March 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 128.64 81.22 58.38 544.10 354.92 53.30 544.10 354.92 53.30
Other Income 0.52 -0.40 -230.00 5.17 5.54 -6.68 5.17 5.54 -6.68
PBIDT 22.11 13.85 59.64 87.58 61.90 41.49 87.58 61.90 41.49
Interest 0.88 1.60 -45.00 2.54 3.59 -29.25 2.54 3.59 -29.25
PBDT 21.23 12.25 73.31 85.04 58.31 45.84 85.04 58.31 45.84
Depreciation 2.38 2.28 4.39 9.33 8.88 5.07 9.33 8.88 5.07
PBT 18.85 9.97 89.07 75.71 49.43 53.17 75.71 49.43 53.17
TAX 6.27 0.01 62600.00 14.07 4.34 224.19 14.07 4.34 224.19
Deferred Tax 0.48 -5.42 -108.86 0.48 -6.10 -107.87 0.48 -6.10 -107.87
PAT 12.58 9.96 26.31 61.64 45.09 36.70 61.64 45.09 36.70
Equity 116.84 99.98 16.86 116.84 99.98 16.86 116.84 99.98 16.86
PBIDTM(%) 17.19 17.05 0.79 16.10 17.44 -7.71 16.10 17.44 -7.71
Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..